3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 1
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Thrombosis
1
Thromboembolism
1
Prostatic Neoplasms
1
Neoplasms
1
Lung Neoplasms
1
Inflammation
1
Immune System Diseases
1
Colonic Neoplasms
1
Cardiovascular Diseases
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
Oxaliplatin
31
Fluorouracil
31
Leucovorin
29
Irinotecan
23
Cetuximab
20
Bevacizumab
16
Capecitabine
13
Gemcitabine
11
pembrolizumab
8
Folfox protocol
7
Cisplatin
7
Carboplatin
7
Paclitaxel
6
Nivolumab
6
Cyclophosphamide
6
trifluridine tipiracil drug combination
5
cediranib
5
Erlotinib Hydrochloride
5
adagrasib
4
Ipilimumab
4
IFL protocol
4
Floxuridine
4
Bortezomib
4
veliparib
3
trametinib
3
sargramostim
3
poly ICLC
3
binimetinib
3
Trifluridine
3
Sorafenib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Colonic Neoplasms
×
Rivaroxaban
×
Clear all
NCT06065592
2023-10-06
CAT_PB
Lebanese University
Phase 1
Unknown
500 enrolled